To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed amount.
Dalton Medicinal Chemistry Partners are utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd.
Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to achieve this milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at BI."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
